COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,673 Articles (22,913 medRxiv, 8,760 bioRxiv)

Most recent first Previous |  Page 509: Articles 5081-5090  | Next

Archetypal analysis of COVID-19 in Montana, USA, March 13, 2020 to April 26, 2022
Stone, E., Landguth, E., Coombs, S.
10.1101/2023.03.06.23286886 — Posted: 2023-03-09
Dosing of convalescent plasma and hyperimmune anti-SARS-CoV-2 1 immunoglobulins: a phase I/II dose finding study
Huygens, S., Preijers, T., Swaneveld, F. H., Kleine Budde, I., GeurtsvanKessel, C., Koch, B. C. P., Rijnders, B. J. A.
10.1101/2023.03.07.23286893 — Posted: 2023-03-09
The impact of signal variability on epidemic growth rate estimation from wastewater surveillance data
Colman, E., Kao, R. R.
10.1101/2023.03.07.23286904 — Posted: 2023-03-09
Generation of a SARS-CoV-2 reverse genetics system and novel human lung cell lines that exhibit high virus-induced cytopathology
Khan, J. Q., Rohamare, M., Rajamanickam, K., Bhanumathy, K. K., Lew, J., Kumar, A., Falzarano, D., Vizeacoumar, F., Wilson, J. A.
10.1101/2023.03.08.531833 — Posted: 2023-03-09
Early transcriptional responses of human nasal epithelial cells to infection with Influenza A and SARS-CoV-2 virus differ and are influenced by physiological temperature
Resnick, J. D., Beer, M. A., Pekosz, A.
10.1101/2023.03.07.531609 — Posted: 2023-03-09
COVID-19 as a continuous-time stochastic process
Lone, I., Jan, P. M.
10.1101/2023.03.08.531718 — Posted: 2023-03-09
Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitor
Chen, X., Huang, X., Ma, Q., Kuzmic, P., Zhou, B., Xu, J., Liu, B., Jiang, H., Zhang, W., Yang, C., Wu, S., Huang, J., Li, H., Long, C., Zhao, X., Xu, H., Sheng, Y., Guo, Y., Niu, C., Xue, L., Xu, Y., Liu, J., Zhang, T., Spencer, J., Deng, W., Chen, S.-H., Xiong, X., Yang, Z., Zhong, N.
10.1101/2023.03.09.531862 — Posted: 2023-03-09
Assessment of the Performance of Expired and Unexpired BinaxNOW COVID Rapid Antigen Test Kits Using Positive and Negative Controls
Vaeth, M. J., Mitchell, A., Sun, K. J., Foyez, M., Byrd, L., Elhabashy, M., Cheema, M., Gupta, I., Purekal, S., Locke, C., Kantsiper, M., Siddiqui, Z. K.
10.1101/2023.03.01.23286637 — Posted: 2023-03-09
The impact of public-initiated COVID-19 risk communication on individual NPI practices
Zele, Y. T., Kumie, A., Hailemariam, D., Wakuma, S., Abegaz, T., Yirsaw, S.
10.1101/2023.03.07.23286938 — Posted: 2023-03-08
Excess Mortality in the Vaccination Era in the United States, By State and 6-Month Period
Faust, J. S., Renton, B., Du, C., Chen, A. J., Li, S.-X., Lin, Z., Krumholz, H. M.
10.1101/2023.03.07.23286927 — Posted: 2023-03-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).